Abstract

Pathogenesis and progression of lung cancer are governed by complex interactions between the environment and host genetic susceptibility, which is further modulated by genetic and epigenetic changes. Autotaxin (ATX, ENPP2) is a secreted glycoprotein that catalyzes the extracellular production of lysophosphatidic acid (LPA), a growth-factor-like phospholipid that is further regulated by phospholipid phosphatases (PLPP). LPA's pleiotropic effects in almost all cell types are mediated through at least six G-protein coupled LPA receptors (LPAR) that exhibit overlapping specificities, widespread distribution, and differential expression profiles. Here we use both preclinical models of lung cancer and clinical samples (from patients and healthy controls) to investigate the expression levels, activity, and biological role of the above components of the ATX/LPA axis in lung cancer. ENPP2 was genetically altered in 8% of patients with lung cancer, whereas increased ATX staining and activity were detected in patient biopsies and sera, respectively. Moreover, PLPP3 expression was consistently downregulated in patients with lung cancer. Comparable observations were made in the two most widely used animal models of lung cancer, the carcinogen urethane-induced and the genetically engineered K-rasG12D -driven models, where genetic deletion of Enpp2 or Lpar1 resulted in disease attenuation, thus confirming a procarcinogenic role of LPA signaling in the lung. Expression profiling data analysis suggested that metabolic rewiring may be implicated in the procarcinogenic effects of the ATX/LPA axis in K-ras- G12D -driven lung cancer pathogenesis.Significance: These findings establish the role of ATX/LPA in lung carcinogenesis, thus expanding the mechanistic links between pulmonary fibrosis and cancer. Cancer Res; 78(13); 3634-44. ©2018 AACR.

Highlights

  • Lung cancer is the most prevalent form of malignancy and the leading cause of global cancer-related mortality; the prognosis for patients with lung cancer remains dismal, with a 5-year survival rate below 20%, for all disease stages combined

  • ENPP2 was in silico discovered to be genetically altered in some patients with lung cancer, whereas increased ATX staining and activity were detected in patients and animal models, accompanied by a downregulation of PLPP3 expression

  • ENPP2 is genetically altered in 8% of patients with lung cancer To explore a possible role of the ATX/lysophosphatidic acid (LPA) axis in lung cancer, we first examined the genomic status of ENPP2, as well as of LPA receptors (LPAR) and phospholipid phosphatases (PLPP), in patients with lung cancer

Read more

Summary

Introduction

Lung cancer is the most prevalent form of malignancy and the leading cause of global cancer-related mortality; the prognosis for patients with lung cancer remains dismal, with a 5-year survival rate below 20%, for all disease stages combined. Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/). The molecular origins of lung cancer lie in complex interactions between the environment and host genetic susceptibility, further modulated by genetic and epigenetic changes, leading to changes in the activation status of oncogenes and tumor suppressor genes [1]. Lung cancer, and especially NSCLC, is considered as a group of distinct diseases with vast genetic and cellular heterogeneity and some genomic alterations are shared among various histologic types, most alterations remain distinct [2]. The identified genomic alterations are not always associated with the activation of the relevant cellular pathways and the corresponding phenotypic aberrations [3], further increasing the complexity of correlating genotypic and phenotypic data

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call